In July, Genentech, a biotechnology company, awarded a $180,000 unrestricted grant to Messengers for Health to promote health equity.
Solo-Dex Nominated for Prestigious 2023 Prix Galien USA Awards
The Galien Foundation has recognized the significant contributions of the Wolf Creek, MT company in the “Best Medical Technology” category.
Inimmune Announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company.
New Diagnostic Tests Could Change Leukemia Prevention and Treatment
A Montana based molecular diagnostic company, Alercell Inc., is pioneering novel techniques to augment the way leukemia is diagnosed, treated and ultimately prevented.
Solo-Dex, Inc. Strikes Groundbreaking Agreement for Distribution in Saudi Arabia of its Fascile(R) Non-Opioid Acute Pain Management Suite
Wolf Creek company Solo-Dex, a leading player in the development, manufacture, and sales of innovative non-opioid acute pain management solutions, is pleased to announce a strategic master distribution agreement with CH Trading Group LLC and Farouk, Maamoun Tamer & Co. This groundbreaking partnership will pave the way for the distribution of Solo-Dex’s revolutionary Fascile® suite of products within the Kingdom of Saudi Arabia.
Alercell celebrates National Cancer Survivors’ Day® 2023
The National Cancer Survivors’ Day Foundation invites all cancer survivors to celebrate on June 4 and Alercell joins all survivors to celebrate another beautiful day of life. The date marks the 36th annual Celebration of Life.
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
Social Anxiety Disorder Affects 15 Million U.S. Adults and is More Common Among Women than Men
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are indicated for the treatment of acute migraine in adults. Strategic acquisition helps build Tonix’s commercial capabilities and infrastructure ahead of potential launch of TNX-102 SL for the treatment of fibromyalgia.
Microbion to Present New Data Demonstrating that Pravibismane Disrupts Bacterial Bioenergetics
Microbion Corporation has announced that the company has been selected to present a poster highlighting the results from an E. coli CRISPR/Cas gene expression knockdown study characterizing pravibismane’s mechanism of action at the ASM Microbe Conference to be held in Houston, TX from June 15-19th, 2023.
MSU Extension and Montana Department of Agriculture join new USDA regional food business center partnership
Montana State University Extension and the Montana Department of Agriculture were recently announced as partners in a $30 million U.S. Department of Agriculture effort to establish a regional center to create opportunities for food producers and increase food security.